RT Journal Article
T1 A relevant IgE-reactive 28 kDa protein identified from Salsola kali pollen extract by proteomics is a natural degradation product of an integral 47 kDa polygalaturonase
A1 Mas, Salvador
A1 Oeo-Santos, Carmen
A1 Cuesta Herranz, Javier
A1 Díaz-Perales, Araceli
A1 Colás, Carlos
A1 Fernández, Javier
A1 Barber, Domingo
A1 Rodríguez, Rosalía
A1 Ríos, Vivian de los
A1 Barderas, Rodrígo
A1 Villalva, Mayte
AB A highly prevalent IgE-binding protein band of 28 kDa is observed when Salsola kali pollen extract is incubated with individual sera from Amaranthaceae pollen sensitized patients. By an immunoproteomic analysis of S. kali pollen extract, we identified this protein band as an allergenic polygalacturonase enzyme. The allergen, named Sal k 6, exhibits a pI of 7.14 and a molecular mass of 39,554.2 Da. It presents similarities to Platanaceae, Poaceae, and Cupressaceae allergenic polygalacturonases. cDNA-encoding sequence was subcloned into the pET41b vector and produced in bacteria as a His-tag fusion recombinant protein. The far-UV CD spectrum determined that rSal k 6 was folded. Immunostaining of the S. kali pollen protein extract with a rSal k 6-specific pAb and LC-MS/MS proteomic analyses confirmed the co-existence of the 28 kDa band together with an allergenic band of about 47 kDa in the pollen extract. Therefore, the 28 kDa was assigned as a natural degradation product of the 47 kDa integral polygalacturonase. The IgE-binding inhibition to S. kali pollen extract using rSal k 6 as inhibitor showed that signals directed to both protein bands of 28 and 47 kDa were completely abrogated. The average prevalence of rSal k 6 among the three populations analyzed was 30%, with values correlating well with the levels of grains/m3 of Amaranthaceae pollen. Sal k 6 shares IgE epitopes with Oleaceae members (Fraxinus excelsior, Olea europaea and Syringa vulgaris), with IgE-inhibition values ranging from 20% to 60%, respectively. No IgE-inhibition was observed with plant-derived food extracts.
PB Elsevier
SN 1570-9639
YR 2017
FD 2017-08
LK https://hdl.handle.net/20.500.14352/18031
UL https://hdl.handle.net/20.500.14352/18031
LA eng
NO Ministerio de Economía y Competitividad (MINECO)
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 2 may 2024